# Do GLP-1 Drugs Affect Breast Surgery? Implants Fared Worse, Flaps Did Not Do GLP-1 drugs affect breast surgery? Implant failure odds were 1.70, breast reduction complications 2.6% vs 1.3%, and free flaps fared no worse | four studies. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/do-glp1-drugs-affect-breast-surgery Updated: 2026-09-18 Published: 2026-09-17 [← Research](https://thisglp.com/research) Evidence # Do GLP-1 Drugs Affect Breast Surgery? Implants Fared Worse, Flaps Did Not Implant failure had 1.70 times the odds in GLP-1 users, and breast reduction complications doubled from 1.3% to 2.6%. Free-flap reconstruction and cancer surgery did not show the same. [This GLP Editorial Team](https://thisglp.com/about)September 20267 min readUpdated September 2026 GLP-1 users against matched non-users · Implant reconstruction · implant failure OR 1.70 · Breast reduction · 2.6% vs 1.3% complications · Cancer surgery · no significant difference · Free-flap reconstruction · 9.0% vs 17.1% complications **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). The answer changes with the operation, and for two of the four studied the risk went up. In implant-based reconstruction, GLP-1 users had higher odds of implant failure, at 1.70 (95% CI 1.18 to 2.45) [\[3\]](https://thisglp.com/research/do-glp1-drugs-affect-breast-surgery#ref-3). After breast reduction, wound complications ran at 2.6% against 1.3% [\[4\]](https://thisglp.com/research/do-glp1-drugs-affect-breast-surgery#ref-4). Free-flap reconstruction showed fewer complications, 9.0% against 17.1% [\[2\]](https://thisglp.com/research/do-glp1-drugs-affect-breast-surgery#ref-2). Breast cancer surgery showed no significant difference, on 209 exposed patients [\[1\]](https://thisglp.com/research/do-glp1-drugs-affect-breast-surgery#ref-1). ## Key takeaways - Implant-based reconstruction, 326 matched GLP-1 users: implant failure OR 1.70, wound-healing complications OR 1.90, readmission or ED visit OR 1.80. - Breast reduction, in people without diabetes: surgical site complications 2.6% against 1.3% within 30 days. - Free-flap reconstruction: composite wound complications 9.0% against 17.1%, with the benefit confined to people without diabetes. - Breast cancer surgery, 750 patients: no significant difference, but every adjusted odds ratio sat above 1. - All four are retrospective record studies. None is a trial. ## Implant-based reconstruction A records study identified 57,987 reconstruction patients between 2014 and 2024, of whom 823 had used a GLP-1 before surgery [\[3\]](https://thisglp.com/research/do-glp1-drugs-affect-breast-surgery#ref-3). After matching on body mass index, comorbidities and timing, 326 implant patients were compared with controls. The odds of implant failure were 1.70 (95% CI 1.18 to 2.45). Wound-healing complications came in at an odds ratio of 1.90. Readmission or an emergency visit was 1.80 (95% CI 1.04 to 3.21). Hematoma, seroma and blood clots did not differ. In the same study, 51 matched patients having autologous reconstruction showed no increased risk. That is a small group, and it cannot rule out a moderate difference. The pattern of one operation faring worse than another echoes [the evidence across four other procedures](https://thisglp.com/research/does-a-glp1-affect-surgery-outcomes). ## Free-flap reconstruction A second records study looked only at free-flap reconstruction from 2012 to 2025 [\[2\]](https://thisglp.com/research/do-glp1-drugs-affect-breast-surgery#ref-2). Anyone with a GLP-1 prescription in the year before surgery counted as a user. After matching, composite wound complications were 9.0% in users and 17.1% in non-users. Surgical site infection was 4.1% against 8.1%, and wound dehiscence 3.8% against 7.8%. The favorable result came from people without diabetes, at 7.9% against 18.6%. In people with diabetes, overall complication rates were comparable. The abstract does not give the size of either cohort. ## Breast reduction A third study excluded diabetes, cancer history and smoking, then matched GLP-1 users to non-users having breast reduction, abdominoplasty or panniculectomy [\[4\]](https://thisglp.com/research/do-glp1-drugs-affect-breast-surgery#ref-4). Wound infection, breakdown or dehiscence within 30 days ran at 2.6% against 1.3% after breast reduction. Both abdominal procedures showed higher rates too. The absolute gap after breast reduction is about one extra complication per 77 operations. ## Breast cancer surgery The fourth study covered 750 patients at one tertiary center between January 2024 and August 2025 [\[1\]](https://thisglp.com/research/do-glp1-drugs-affect-breast-surgery#ref-1). Of those, 209 had GLP-1 use in the 30 days before surgery, verified against pharmacy records. After adjustment, surgical site infection had an odds ratio of 1.28 (95% CI 0.81 to 2.03). Seroma was 1.22 (95% CI 0.83 to 1.79). Flap necrosis of grade II or worse was 1.41 (95% CI 0.83 to 2.40). A null on 209 patients None of the three is significant, because every interval crosses 1. Every point estimate also sits above 1, and two of the upper bounds run past 2. With 209 exposed patients, an increase of that size could go undetected. This result is the absence of a detected difference, not evidence that there is none. The exposed patients also had higher body mass index and more diabetes before surgery. The authors adjusted and weighted for that. Measured differences can be corrected; unmeasured ones cannot. The same limit runs through [the spinal fusion databases](https://thisglp.com/research/do-glp1-drugs-affect-spinal-fusion-surgery). ## What none of these measured Anesthetists ask about these drugs for a different reason: slowed stomach emptying and the risk of inhaling stomach contents at induction. None of the four studies measured that. The digestive side of the question is covered in [the gastroparesis guide](https://thisglp.com/research/do-glp1-drugs-cause-gastroparesis). The practical step does not depend on which way these results settle. Tell the surgical and anesthetic team you are taking one, and ask whether to pause it. That timing is their decision. Specialist guidance on what proper care around these drugs looks like is summarized in [what a GLP-1 provider should do](https://thisglp.com/research/what-should-a-glp1-provider-actually-do). ## Frequently asked Is it safe to take a GLP-1 before breast surgery? It depends on the operation. Implant-based reconstruction and breast reduction both had more complications in GLP-1 users. Free-flap reconstruction had fewer, and breast cancer surgery showed no significant difference on 209 exposed patients. Do GLP-1 drugs cause implant failure after reconstruction? In one matched records study of 326 implant patients, GLP-1 users had 1.70 times the odds of implant failure (95% CI 1.18 to 2.45). It is an association in retrospective data, not a trial result. Does a GLP-1 affect healing after breast reduction? Wound complications within 30 days ran at 2.6% in GLP-1 users against 1.3% in matched non-users, in a study that excluded people with diabetes. Should I stop my GLP-1 before breast surgery? That is a decision for the surgical and anesthetic team. Tell them you are taking one; the timing of any pause is theirs to set. ## Sources 1. \[1\] Alsaleh N, Seif-Eldein NA, El Malky AM, Al Hashem H, Idriss H (2026). Perioperative GLP-1 Receptor Agonist Use and 30-Day Outcomes After Breast Cancer Surgery: A Retrospective Cohort Study World Journal of Surgery. [PMID 42444315](https://pubmed.ncbi.nlm.nih.gov/42444315/) 2. \[2\] Ha J, Lester ER, De May H, Somers S, Eddington D, Agarwal JP, et al. (2026). GLP-1 Receptor Agonist Use and Wound Outcomes After Free Flap Breast Reconstruction Journal of Reconstructive Microsurgery. [PMID 42013898](https://pubmed.ncbi.nlm.nih.gov/42013898/) 3. \[3\] Hamzeh BF, Orear CR, Mardourian M, Keeter C, Egan KG, Winocour J, et al. (2026). Effects of GLP-1 Receptor Agonists on Breast Reconstruction Outcomes: A Large-Database Retrospective Study Journal of Clinical Medicine. [PMID 42452504](https://pubmed.ncbi.nlm.nih.gov/42452504/) 4. \[4\] Lee CC, Newland M, Yau A, Chroneos R, Johnson TS (2026). Impact of GLP-1 Agonist on Surgical Wound Complications after Plastic and Reconstructive Surgery: A Propensity-Matched Cohort Large Database Analysis Plastic and Reconstructive Surgery. [PMID 41364427](https://pubmed.ncbi.nlm.nih.gov/41364427/) ## Where to get it ### Best GLP-1 injections Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured. [Compare providers →](https://thisglp.com/best/compounded-semaglutide) ## More in Evidence - [ 150 minutes · Weekly activity goal · 2 days · Muscle strengthening · Adapt · Symptoms and ability ### Exercise on Ozempic: Building Strength Without Ignoring Symptoms ](https://thisglp.com/research/exercise-on-ozempic) - [ STEP 1, semaglutide 2.4 mg vs placebo, % change at 68 weeks · LDL cholesterol · −2.5% vs +1.3% · Total cholesterol · −3.3% vs +0.1% · HDL cholesterol · +5.2% vs +1.4% · Triglycerides · −21.9% vs −7.3% · Wegovy label, Table 13. Adults without diabetes. Ozempic doses are lower. ### Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show ](https://thisglp.com/research/does-ozempic-lower-cholesterol) - [ Where the insulin reduction came from, units per day · week 4 · 13.4 total · week 26 · 21.9 · the drug itself · the weight loss · The drug’s own contribution barely moved: 11.1 then 11.4. · Everything added between weeks 4 and 26 came from weight. ### Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found ](https://thisglp.com/research/semaglutide-in-type-1-diabetes)